Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 501 to 525 of 2570

TitleReference numberPublishedLast updated
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Transperineal biopsy for diagnosing prostate cancerHTG680
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcersHTG677
MRI fusion biopsy systems for diagnosing prostate cancerHTG678
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuriesHTG679
Head injury: assessment and early managementNG232
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Diabetes (type 1 and type 2) in children and young people: diagnosis and managementNG18
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessmentHTG674
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Metastatic malignant disease of unknown primary origin in adults: diagnosis and managementCG104
Fasciotens for abdominal wall closureMIB321
Tezepelumab for treating severe asthmaTA880
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Lumasiran for treating primary hyperoxaluria type 1HST25

Results per page

  1. 10
  2. 25
  3. 50
  4. All